November 8th 2024
Overall, 76% of patients with a CD70 TPS of at least 50% achieved a reduction in tumor burden.
September 25th 2024
September 19th 2024
Disparities found in clinical trial participation for patients with renal cell carcinoma
April 3rd 2023“These disparities are concerning as the generalizability of clinical trial results relies on the assumption that the population of patients included in a clinical trial represents the overall population of patients with the disease," says Brian M. Shinder, MD.
Dr. Wood on rollout of same-day discharge following robotic partial nephrectomy
February 14th 2023“I am seeing this process rapidly expand, particularly with the use of the single-port robot, which offers additional benefits to things like pain control and helps to further expedite early discharge,” Andrew Wood, MD.
Race-based adjustment of eGFR: Current opinions and impact on urologic oncology
January 19th 2023“As other factors such as access to care, socioeconomic conditions, patient preference, and other unknown confounders might have played a role in the observed disparity, it is still unclear whether overestimating the postoperative eGFR of Black patients contributes to the lower use of nephron-sparing approaches in this population,” the authors write.
Dr. Bukavina and Dr. Psutka share take-homes from kidney cancer epidemiology paper
November 25th 2022“We need to continue to push the field forward, and the way we do that is to evaluate the risk factors and to stratify patients based on their risk factors and their genetic components,” says Laura Bukavina, MD, MPH.
Analysis shows promise of tivozanib in patients with nccRCC
November 22nd 2022“Due to the rarity and poor molecular characterization of nccRCC, there is an underrepresentation in clinical trials evaluating patients with this type of RCC; because of this, patients are often treated with non-tailored therapies,” the researchers wrote.
Dr. McKay on the shifting second-line paradigm in advanced renal cell carcinoma
October 26th 2022Rana McKay, MD, says that given the frontline shift from anti-VEGF monotherapy to immunotherapy doublets for advanced renal cell carcinoma, many of the studies informing the second-line setting have become “somewhat antiquated.”
Stereotactic ablative radiation effective in systemic therapy–naïve oligometastatic kidney cancer
August 23rd 2022“There has never been a clinical trial for these patients. It is unclear whether these patients should be treated with medication, surgery, or another approach. This represents an unmet medical need,” said Raquibul Hannan, MD, PhD.